Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-31
2010-12-14
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07851455
ABSTRACT:
Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic
eoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter or a MN gene promoter fragment comprising the HIF-1 consensus binding sequence, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. Further, the hypoxia inducibility of the MN gene and the uses of such inducibility are disclosed.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5942434 (1999-08-01), Ratcliffe et al.
patent: 6265390 (2001-07-01), Ratcliffe et al.
patent: 6436654 (2002-08-01), Berkenstam et al.
patent: WO 88/08854 (1988-11-01), None
patent: WO 93/18152 (1993-09-01), None
patent: WO 95/34650 (1995-12-01), None
patent: WO 01/23426 (2001-04-01), None
Anton et al., “Localized renal-cell carcinoma: detection of abnormal cells in peritumoral tissue. A cytophotometry and immunocytochemistry study,”World J. Urol., 13(3): 149-152 (1995).
Bander et al., “Renal cancer imaging with monoclonal antibody G250,”J. Urol., 155 (5 Suppl.): 583A (Abstract 1088) (1996).
Beasley et al., “Carbonic Anhydrase IX, an Endogenous Hypoxia Marker, Expression in Ilead and Neck Squamous Cell Carcinoma and its Relationship to Hypoxia, Necrosis, and Microvessel Density,”Cancer Research, 61(13): 5262-5267 (Jul. 1, 2001).
Blancher et al., “Relationship of Hypoxia-inducible Factor (H1F)-1alpha and HIF-2alpha Expression to Vascular Endothelial Growth Factor Induction and Hypoxia Survival in Human Breast Cancer Cell Lines,”Cancer Research, 60: 7106-7113 (Dec. 15, 2000).
Brewer et al., “Enhanced expression of MN protein in cervical carcinomas: Western blot analysis correlates with Immunohistochemical staining,”Proceedings of the American Association for Cancer Research Annual Meeting, 35: 607 (Abstract No. 3621) (1994).
Brewer et al., “A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN,”Gynecologic Oncology, 63: 337-344 (1996).
Brewer et al., “Vascular endothelial growth factor (VEGF) protein isoform alterations in cervical carcinoma and clinical correlation,”Gynecologic Oncology, 68(1): 75 (Abstract No. 8) (Jan. 1998).
Chia et al., “Prognostic Significance of a Novel Hypoxia Regulated Marker, Carbonic Anhydrase IX (MN/CA IX), in Invasive Breast Cancer,”Breast Cancer Research and Treatment, 64(1): 43 (Nov. 2000).
Chia et al., “Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma,”Journal of Clinical Oncology, 19(16): 3660-3668 (Aug. 15, 2001).
Cho et al., “Hypomethylation of MN/CA9 promoter region contributes to its expression in human renal cell carcinomas,” Abstract 2922,Proceedings of the American Association for Cancer Research, Apr. 10-14, 1999, Philadelphia, PA, vol. 40 (Mar. 1999).
Costa et al., “MN Protein Immunolocalization in Uterine Cervix Carcinoma With Glandular Differentiation—A Clinicopathologic Study of a New Cancer-specific Biomarker,”International Journal of Surgical Pathology, 3(2): 73-82 (1995).
Costa, M., “MN and K167 (MIB-1) in Uterine Cervix Carcinoma: Novel Biomarkers With Divergent Utility,”Human Pathology, 27(3): 217-219 (Mar. 1996).
Dachs and Tozer, “Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploritaion,”European Journal of Cancer, 36: 1649-1660 (2000).
de la Taille, et al., “Biomarkers of renal cell carcinoma Past and future considerations.”Urologic Oncology, 5: 139-148, (2000).
Diagnostics Intelligence, 10(5): 11“Cervical marker can help resolve ambiguous Pap smears” (1998).
Divgi et al., “Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250,”European Journal of Nuclear Medicine, 19(8): 578 (Abstract 121-3) (Aug. 23, 1992).
Divgi et al., “Radioimmunotherapy (RIT) with I-131 Monoclonal Antibody (Mab) G250 in Metastatic Renal Cancer,”Proceedings of the 41st Annual Meeting, 35(5): 101P (Abstract #401) (May 1994).
Divgi et al., “Radioinimunotherapy with I-131-G250 in Metastatic Renal Cell Cancer (RCC),”J. Nucl. Med., 36 (5 Suppl.): 913P (Abstract 956; May 1995).
Folkman, J., “What is the Evidence That Tumors Are Angiogenesis Dependent?”Journal of the National Cancer institute, 82(1): 4-6 (Jan. 3, 1990).
Frohman et al., “Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer,”PNAS(USA), 85: 8998-9002 (Dec. 1988).
Froseh et al., “Cloning and characterisation of an immunodominant major surface antigen ofEchinococcus multilocularis,” Molecular and Biochemical Parasitology, 48: 121-130 (1991).
Giatromanolaki et al., “Patterns of expression of three hypoxia regulated proteins (Hypoxia Inducible Factors HIF1 /HIF1 and Carbonic Anhydrase CA9) in squamous cell carcinoma of the lung,”Virchows Archiv, 439(3): 349 (Sep. 2001).
Giatromanolaki et al., “Patterns of expression of three hypoxia regulated proteins (Hypoxia Inducible Factors HIF1a/HIF1b and Carbonic Anhydrase (CA9) in squamous cell lung carcinoma,”European Journal of Cancer, 37(Supp. 6): S155 (Oct. 2001).
Giatromanolaki et al., “Expression of Hypoxia-Inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer,”Cancer Research, 61(21): 7992-7998 (Nov. 1, 2001).
Griffiths et al., “The macrophage—a novel system to deliver gene therapy to pathological hypoxia,”Gene Therapy, 7: 255-262 (2000).
Harris, A.L., “Hypoxia regulation transcriptome: Implications for tumour angiogenesis and therapy,”British Journal of Cancer, 85(Supp. 1): pp. 4 (Jul. 2001).
Ivanov et al., “Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Ilippel-Lindau transgenes,”PNAS(USA) 95: I2956-I2601 (Oct. 1998).
Ivanov et al., “Activation of transmembrane carbonic anhydrases in cancer development,” Abstract 4549,Proceedings of the American Association for Cancer Research, Apr. 10-14, 1999, Philadelphia, PA, vol. 40 (Mar. 1999).
Ivanov et al., “Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer,”American Journal of Pathology, 158(3): 905-919 (Mar. 2001).
Kaluz et al., “Transcriptional Regulation of the MN/CA9 Gene Coding for the Tumor-associated Carbonic Anhydrase IX,”The Journal of Biological Chemistry, 274(46): 32588-32595 (Nov. 12, 1999).
Kaluzova et al., “P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu Cells,”Biochemica et Biophysica Acta, 1491: 20-26 (2000).
Kaluzova et al., “Characterization of the MN/CA 9 promoter proximal region: a role for specificity protein (SP) and activator protei 1 (AP1) factors,”Biochemical Journal, 359(Pt 3): 669-677 (Nov. 1, 2001).
Karhumaa et al., “
Harris Adrian L.
Ratcliffe Peter J.
Harland Joan C.
Helms Larry R.
Lauder Leona L.
Natarajan Meera
Shimel Barbara A.
LandOfFree
MN gene and protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MN gene and protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MN gene and protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237810